# Clinical Trials Data EGFR - Document 74

# A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI

## Clinical Trial: https://clinicaltrials.gov/study/NCT01763307

"eligibilityCriteria": "Inclusion Criteria:\n\n\* metastatic colon cancer patients\n\* male or female\n\* age\\> 18\n\* treated EGFRI\n\nExclusion Criteria:\n\n\* prior treatment with EGFRI",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
No. The inclusion criteria specify "treated EGFRI" (EGFR inhibitor), while the exclusion criteria specify "prior treatment with EGFRI". These criteria contradict each other. Since exclusion criteria overrule inclusion criteria, a patient who has been treated with an EGFRI would ultimately be \*excluded\* from the trial. Having an EGFR mutation itself doesn't disqualify the patient, but the prior treatment with EGFRI does.